Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic hypernephroma Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Aminoacridines
  • Kidney Neoplasms

abstract

  • 4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA), a new acridine derivative thought to function by intercalation and external binding with DNA, was found in preclinical studies to possess antitumor activity against various murine tumors. In phase I clinical trials responses were observed in a variety of neoplasms, particularly in leukemia and breast cancer. Since renal cell carcinoma is a chemotherapeutically resistant tumor, a disease-oriented phase II trial of AMSA in patients with objectively measurable metastatic hypernephroma was initiated and forms the basis of this report.

publication date

  • December 1980

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 6892892

Additional Document Info

start page

  • 183

end page

  • 5

volume

  • 64

number

  • 1